KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Novartis Ag (NVS) FCF Payout Ratio (2009 - 2012)

Novartis Ag recorded quarterly FCF Payout Ratio of 0.0 in Q2 2012, up 85.94% quarter-over-quarter from 0.04 in Q2 2011, and up 85.94% year-over-year from 0.0 in Q3 2011.

Novartis Ag's FCF Payout Ratio history runs 4 years deep, the most recent figure standing at 0.0 for Q2 2012.

  • In Q2 2012, FCF Payout Ratio rose 85.94% year-over-year to 0.0; the TTM figure through Jun 2012 stood at 1.95 (up 18.3% YoY), while the FY2025 annual figure was 0.44, down 5.28% from the prior year.
  • FCF Payout Ratio came in at 0.0 for Q2 2012 at Novartis Ag, up from 0.04 in the prior quarter.
  • In the past five years, FCF Payout Ratio ranged from a high of 0.0 in Q2 2009 to a low of 1.7 in Q1 2009.
  • A 4-year average of 0.5 and a median of 0.04 in 2010 frame the typical range for FCF Payout Ratio.
  • Across the five-year window, FCF Payout Ratio plunged 1473.35% in 2010 and surged 85.94% in 2012, its largest moves.
  • Novartis Ag's FCF Payout Ratio stood at 0.0 in 2009, then slumped by 1473.35% to 0.05 in 2010, then surged by 30.34% to 0.04 in 2011, then soared by 85.94% to 0.0 in 2012.
  • According to Business Quant data, FCF Payout Ratio over the past three periods registered 0.0, 0.04, and 0.05 for Q2 2012, Q2 2011, and Q2 2010 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Cover (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.51
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 2.14
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.87
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.72
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.92
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.43
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 1.12
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 1.69
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2012 0.00
Jun 30, 2011 -0.04
Jun 30, 2010 -0.05
Mar 31, 2010 -1.24
Jun 30, 2009 0.00
Mar 31, 2009 -1.70